Johnson & Johnson (NY: JNJ )

145.48 -1.00 (-0.68%)
Official Closing Price Updated: 7:00 PM EDT, Jul 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,260,351
Open 146.40
Bid (Size) 145.48 (5)
Ask (Size) 145.90 (10)
Prev. Close 146.48
Today's Range 145.25 - 147.22
52wk Range 143.13 - 175.97
Shares Outstanding 2,628,679,824
Dividend Yield 3.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
7 Diversified Income Powerhouses for Lifelong Cash Flow
Explore diversified income stocks that provide stable cash flow and growth potential for long-term investors seeking lifelong income. 
Via InvestorPlace

Performance

YTD
-9.06%
-9.06%
1 Month
-1.12%
-1.12%
3 Month
-4.03%
-4.03%
6 Month
-9.94%
-9.94%
1 Year
-8.80%
-8.80%

More News

Read More
3 Rock-Solid Income Machines to Hold for Decades
Via InvestorPlace
3 Dividend Aristocrats Now Cheaper Than During the 2008 Financial Crisis
Via InvestorPlace
What's Going On With Johnson and Johnson Shares Friday?
Via Benzinga
Nasdaq vs. Dow Jones: A Detailed Breakdown of Stock Indexes
Via MarketBeat
Topics Stocks
Exposures US Equities
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
7 Blue-Chip Cash Cows to Milk for Steady Income
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
Via MarketBeat
Topics ETFs
7 Safe Haven Stocks to Buy Before the Next Market Correction
Via InvestorPlace
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Via Benzinga
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
JNJ Should Rally Soon Or See 3 Swings Higher At Least
Via Talk Markets
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Via Benzinga
Topics Stocks
Exposures US Equities
"Rule Breaker Investing" Mailbag: Talking Stocks and Options
Via The Motley Fool
3 Retirement All-Stars for Steady Growth and Income
Via InvestorPlace
Topics Retirement
Exposures Pension
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Via InvestorPlace
Judge Blocks Cancer Victims' Attempt To Stop Johnson & Johnson Bankruptcy Plan
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
3 Magnificent Stocks Retirees Can Buy and Hold Forever
Via The Motley Fool
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
Via InvestorPlace
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.